CAD patients with CAE were detected to have significantly higher levels of certain activation markers such as CD11b (44.5 ± 5.0 versus 30.0 ± 3.8 and 20.9 ± 3.6), CD11c, (96.3 ± 10.9 versus 66.1 ± 6.4 and 50.4 ± 5.7) CD54 (45.6 ± 6.7 versus 31.1 ± 4.9 and 20.8 ± 3.2), CD83 (44.6 ± 6.1 versus 30.8 ± 2.4 and 25.6 ± 2.8), CD86 (50.7 ± 5.0 versus 39.2 ± 4.1 and 29.5 ± 4.1) and MHC Class II (112.4 ± 11.3 versus 73.1 ± 9.5 and 54.5 ± 4.5) molecules on the surface of mDCs in comparison to CAD patients without CAE and normal subjects with angiographically normal coronary arteries (Figure 1). This evidence concerns the gene CD86 and coronary artery disorder.